Alendronate-hydroxyapatite nanocomposites and their interaction with osteoclasts and osteoblast-like cells

被引:139
作者
Boanini, Elisa [1 ]
Torricelli, Paola [2 ]
Gazzano, Massimo [3 ]
Giardino, Roberto [2 ,4 ]
Bigi, Adriana [1 ]
机构
[1] Univ Bologna, Dept Chem G Ciamician, Bologna, Italy
[2] Rizzoli Orthopaed Inst, Res Inst Codivilla Putti, Dept Expt Surg, Bologna, Italy
[3] ISOF CNR, Dept Chem G Ciamician, Bologna, Italy
[4] Univ Bologna, Dept Surg Pathophysiol, Bologna, Italy
关键词
hydroxyapatite; bisphosphonate; osteoblast; osteoclast;
D O I
10.1016/j.biomaterials.2007.10.040
中图分类号
R318 [生物医学工程];
学科分类号
0831 [生物医学工程];
摘要
The direct synthesis of hydroxyapatite in the presence of bisphosphonates is quite difficult due to the great affinity for calcium of these compounds, which are widely used in the treatment of pathologies related to bone loss. We recently developed a new method which allowed to synthesize alendronate-hydroxyapatite composite nanocrystals with a bisphosphonate content up to about 7 wt%. Herein we report the results of an in vitro study aimed to investigate the effects of alendronate incorporation into hydroxyapatite on bone cells response. Osteoblast-like MG63 cells and human osteoclasts were cultured on nanocrystals at different alendronate content (3.9, 6.2, 7.1 wt%). MG63 cells cultured on the composite nanocrystals display normal morphology, good proliferation and increased values of the differentiation parameters. In particular, when cultured on composites at relatively high alendronate contents, osteoblasts display increased values of alkaline phosphatase activity (ALP), collagen type 1, and osteocalcin production, as well as significant decrease of matrix metalloproteinases (MMP-1 and MMP-13) production, with respect both to the control and to pure hydroxyapatite nanocrystals. It follows that the presence of alendronate enhances osteoblast activation and extracellular matrix mineralization processes, without any abnormal collas en degradation. The osteoclast number on the composite nanocrystals decrease indicating that the bisphosphonate exerts its inhibitory effect on osteoclast proliferation even when incorporated into hydroxyapatite. (c) 2007 Elsevier Ltd. All rights reserved.
引用
收藏
页码:790 / 796
页数:7
相关论文
共 29 条
[1]
Atsushi E, 2003, BIOMATERIALS, V24, P831
[2]
Composite nanocrystals provide new insight on alendronate interaction with hydroxyapatite structure [J].
Boanini, Elisa ;
Gazzano, Massimo ;
Rubini, Katia ;
Bigi, Adriana .
ADVANCED MATERIALS, 2007, 19 (18) :2499-+
[3]
BRUCKNER S, 1988, CHIM IND-MILAN, V70, P48
[4]
Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis [J].
Chesnut, CH ;
Skag, A ;
Christiansen, C ;
Recker, R ;
Stakkestad, JA ;
Hoiseth, A ;
Felsenberg, D ;
Huss, H ;
Gilbride, J ;
Schimmer, RC ;
Delmas, PD .
JOURNAL OF BONE AND MINERAL RESEARCH, 2004, 19 (08) :1241-1249
[5]
Mineralization and the expression of matrix proteins during in vivo bone development [J].
Cowles, EA ;
DeRome, ME ;
Pastizzo, G ;
Brailey, LL ;
Gronowicz, GA .
CALCIFIED TISSUE INTERNATIONAL, 1998, 62 (01) :74-82
[6]
Recent advances in understanding the mechanism of action of bisphosphonates [J].
Coxon, Fraser P. ;
Thompson, Keith ;
Rogers, Michael J. .
CURRENT OPINION IN PHARMACOLOGY, 2006, 6 (03) :307-312
[7]
Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients [J].
Dobnig, H ;
Hofbauer, LC ;
Viereck, V ;
Obermayer-Pietsch, B ;
Fahrleitner-Pammer, A .
OSTEOPOROSIS INTERNATIONAL, 2006, 17 (05) :693-703
[8]
In vitro behaviour of osteoblasts cultured on orthopaedic biomaterials with different surface roughness, relative to uncoated and fluorohydroxyapatite-coated, the in vivo osteointegration rate [J].
Fini, M ;
Giardino, R ;
Borsari, V ;
Torricelli, P ;
Rimondini, L ;
Giavaresi, G ;
Aldini, NN .
INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS, 2003, 26 (06) :520-528
[9]
INHIBITION OF BONE-RESORPTION BY BISPHOSPHONATES - INTERACTIONS BETWEEN BISPHOSPHONATES, OSTEOCLASTS, AND BONE [J].
FLANAGAN, AM ;
CHAMBERS, TJ .
CALCIFIED TISSUE INTERNATIONAL, 1991, 49 (06) :407-415
[10]
Bisphosphonates: Mechanisms of action [J].
Fleisch, H .
ENDOCRINE REVIEWS, 1998, 19 (01) :80-100